Phaseline

Companies › AC Immune

AC Immune: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Neurology, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACI-7104.056
Adjuvanted alpha-synuclein peptide conjugate vaccine
SNCAPhase 2Parkinson DiseaseJun 2028
ACI-19764
NLRP3 inflammasome inhibitor
NLRP3Phase 1Healthy ParticipantsDec 2026
ACI-24.060–Phase 1Amyloid PlaqueApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07463196ACI-19764Phase 1Healthy ParticipantsMetabolic and endocrineDec 2026
NCT06015841ACI-7104.056Phase 2Parkinson DiseaseNeurologyJun 2028
NCT05462106ACI-24.060Phase 1Amyloid PlaqueNeurologyApr 2029

From the company's SEC filings

Cash of 27m CHF on 2025-12-31; operating cash outflow about 69m CHF a year; runway about 5 months at that burn, to May 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

NLRP3 (1) SNCA (1)

Companies with the same targets

Highlightll Pharmaceutical (USA) Olatec Therapeutics Teva Branded Pharmaceutical Products R&D Regeneron Pharmaceuticals Roche XingImaging

Companies built like this

IGC Pharma Denali Therapeutics Cytopeutics Sdn. Bhd. Larimar Therapeutics NKGen Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.